創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
20/05/30 GEM187 Mesenchymal stem cell Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), COVID-19 Implant (allo- genic) Cell IND GEM187 is a fresh (non-frozen) human allogenic umbilical cord tissue derived mesenchymal stem cells (hUC-MSC) product.
- Proprietary manufacturing process with no risk of contamination.
- “Youngest” adult MSC with robust proliferation capacity.
- Highly scalable to achieve enough cells.
- Superior biological functions: optimal cell viability and biological functions maintained for therapeutic use.
問合せ
20/05/29 GEM186 Innate Immune System Activator Solid tumor i.t. Microbial Phase 1 Co-activation of multipole innate immune pathways in tumor dendritic cells.
Dose dependent anti-tumor activities in allogenic models.
Low systemic risk
問合せ
20/05/12 GEM185 GLP-1/GIP dual agonist Obesity, diabetes s.c. Peptide IND reaedy GEM185 is an injectable (QD) dual agonist for GLP-1R and GIPR. Preclinical studies have shown that GEM185 is more effective in improving diabetes and obesity than GLP-1R agonism only. In addition, GEM185 has been shown to improve liver parameters in diabetic and obesity conditions in preclinical research. Hence, GEM182 may be superior to the GLP-1R agonist in improving diabetes, obesity, and non-alcoholic steatohepatitis (NASH). In a preclinical study, GEM185 showed better efficacy in improving glycemic control and an almost same efficacy in decreasing body weight compared to tirzepatide, a Lilly’s Ph3 program. A long-acting formulation, which is likely to maximize its therapeutic efficacy, are under development. A phase 1 study (first-in-human study), starting in 2020, is being organized in the UK. 問合せ
20/05/12 GEM184 GPR40 full agonist Obesity, diabetes, NAFLD/NASH Oral Small molecule Phase 1 A first-in-class GPR40 full agonist stimulating multiple islet (insulin, glucagon) and gut hormones (GLP-1, GIP, and PYY). GEM184 is much more effective in improving glucose control than DPP-4 inhibitors and in preclinical models. In addition to glucose-lowering effects, GEM184 effectively decreases body weight in overweigh condition via stimulating gut hormones. By binding to a site independent of the fasiglifam binding site, GEM184 induces a similar therapeutic efficacy with much lower exposure (~1/270) compared to fasiglifam in diabetic models. A lower plasma exposure mitigates the risk of side effects including liver toxicities reported with fasiglifam. In addition, glucagon an GLP-1 stimulation by GEM184 induces therapeutic benefits on NAFLD/NASH conditions, in which DPP4 inhibitor and SGLT2 inhibitor were almost ineffective. 問合せ
20/05/12 GEM183 Direct renin inhibitor (DRI) Blood pressure control and/or prevention of heart failure in patients with chronic hemodialysis i.v. Small molecule Preclinical Injectable formulation of GEM182 (oral formulation in phase-2b), is also being developed for potential use for better blood pressure control and/or prevention of heart failure by chronic intravenous treatment three times per week via vascular access established in patients with chronic hemodialysis. Renin inhbitor may be suitable for such patients who often exhibit hyperreninemia potentially due to residual function of juxtaglomerular apparatus as well as reduced renal blood flow after start of the hemodialysis. Although dialysis patients are mostly unavoidable from hypertension, no optimal treatment has been available yet. GEM183 can fulfill such such rapid growing huge unmet medical needs.
Licensing discussion is available except for China.
問合せ
20/05/12 GEM182 Direct renin inhibitor (DRI) Hypertension (HP), diabetic nephropathy (DKD), chronic hemodialysis, heart failure Oral Small molecule HP : Phase 2 ready, DKD: Phase 3 ready A 2nd generation DRI with better renoprotective effects than ACEi/ARB. Better hypotensive effects than aliskiren is expected due to higher BA, less variability and no food effect following oral treatment. Prolonged renal localization, blood pressure independent renoprotection and positive effect on renal blood flow are evidenced by DRIs. In clinical trials of GEM182 in T2DM patients with microalbuminuria, dose-dependent UACR reduction and increases in remission rate from albuminuria were also seen.
This compound have been developed as mono-therapy (not combined with ACEi/ARB). Therefore, GEM182 has no safety issues seen in aliskiren's ALTITUDE trial due to RAS dual brockade.
Injectable formalution is also developed (ref. GEM183).
Licensing discussion is available except for China.
問合せ
20/05/11 GEM181 Selective HDAC8 inhibitor Solid tumor Oral Small molecule Phase 1 Through several mechanisms exhibited tumor inhibitory activity against many cancers, especially with high HDAC8 protein expression.
Advantages of GEM181
- Able to pass the BBB
- Suppresses angiogensis
- Side effects less than those of curretly marketed drugs
- Simple synthetic method
問合せ
20/05/08 GEM180 Contrasting MRI Contrasting i.v. Nano particle Phase 2 GEM180 is a MRI contrast meium whivch can detect more small liver lesion, compared to marketed product, because of the better contrast. Biopsy confirmed the number of small nodules by GEM180. GEM180 has better imaging results (higher percent signal intensity loss (PSIL) and better consistency) from CT001. So far no obvious severe adverse events seen. Comprehensive patent portofolio exist globally. 問合せ
20/05/08 GEM179 Iron supply Iron deficienmt anemia i.v. Nano particle Phase 2 GEM179 is a pegylated Iron oxide nano particle (IOP) with high macropharge uptake efficiency. GEM179 provide higher efficacy and better safety profilres (serum iron, ROS, hypersensitivity, iFGF23). Comprehensive patent portofolio exist globally. 問合せ
20/05/07 GEM178 Anti-VEGF and antibacterial activities Acne, hypertrophic scar, dermatitis Topical skin Small molecule Preclinical - The first topical drug for treating skin redness by inhibiting VEGF.
- Skin redness originates from the neovascularization. Redness of human acne was rapidly removed in a few days with no irritation nor discomfort.
- Strongly inhibited P. acne with an effectiveness >100X clindamycin.
- A 505(b)2 path available.
- US Patent granted.
問合せ